ClinicalTrials.gg

Program

Interferon beta-1a

Also written as “Rebif®”, “RNF” and “Rebif”.

Its studies are mostly in Multiple Sclerosis · Multiple Sclerosis, Relapsing-Remitting · COVID-19 · Colitis, Ulcerative · Pneumonia, Viral, led by 7 companies.

Furthest: phase 4, since Sep 13, 200553 company-led studies, 0 open or running

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Biogen230 open or runningphase 4since Sep 13, 2005Dec 15, 2004none ahead
Merck KGaA, Darmstadt, Germany210 open or runningphase 4since Feb 23, 2004Feb 23, 2004none ahead
Faron Pharmaceuticals30 open or runningphase 3since Nov 24, 2015Nov 24, 2015none ahead
Biocad20 open or runningphase 3since May 29, 2015Jan 10, 2013none ahead
Cinnagen20 open or runningphase 3since Jan 17, 2022Jul 14, 2018none ahead
Azidus Brasil10 open or runningphase 1since Nov 13, 2009Nov 13, 2009none ahead
Trio Medicines10 open or runningphase 1since May 20, 2013May 20, 2013none ahead

Also a collaborator on its studies: toray-industries-inc, Pfizer, gesellschaft-fu-r-therapieforschung-mbh, merck-serono-s-p-a-italy, merck-serono-s-a-s-france, emd-serono-canada-inc, elan-pharmaceuticals, merck-pte-ltd-singapore and merck-serono-international-sa.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

Before these, 39 studies since Feb 23, 2004.

  1. Jan 10, 2013Biocad's first study: phase 1 study in HealthyNew to BiocadBiocad · NCT01766024 · 32 enrolled · Russian Federation
  2. Feb 12, 2013Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT01791244 · 93 enrolled · Germany, Sweden
  3. May 20, 2013Trio Medicines's first study: phase 1 study in Multiple SclerosisNew to Trio MedicinesTrio Medicines · NCT01863069 · 77 enrolled · United Kingdom
  4. Feb 13, 2014Phase 4 study in Multiple Sclerosis, Relapsing-RemittingMerck KGaA, Darmstadt, Germany · NCT02064816 · 200 enrolled · Germany
  5. Apr 15, 2014Phase 4 study in Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02117050 · 1 enrolled · United States
  6. Sep 29, 2014Phase 4 study in Relapsing Multiple SclerosisMerck KGaA, Darmstadt, Germany · NCT02254304 · 106 enrolled · Germany
  7. Oct 17, 2014Phase 1 study in Multiple SclerosisBiogen · NCT02269930 · 30 enrolled · United States
  8. May 29, 2015Phase 3 study in Multiple SclerosisBiocad · NCT02727907 · 163 enrolled · Russian Federation
  9. Nov 24, 2015Faron Pharmaceuticals's first study: phase 3 study in Respiratory Distress SyndromeNew to Faron PharmaceuticalsFaron Pharmaceuticals · NCT02622724 · 301 enrolled · Belgium, Czechia, Finland and more
  10. Jan 26, 2017Phase 4 study in Multiple Sclerosis, Relapsing-RemittingBiogen · NCT03177083 · 80 enrolled · Portugal
  11. Mar 3, 2017Phase 2 study in Multiple Organ FailureFaron Pharmaceuticals · NCT03119701 · 40 enrolled · Estonia, Finland, Lithuania
  12. Jul 14, 2018Cinnagen's first study: phase 1 study in BioequivalenceNew to CinnagenCinnagen · NCT03614715 · 40 enrolled · Finland
  13. Apr 22, 2021Phase 2 study in COVID-19Faron Pharmaceuticals · NCT04860518 · 7 enrolled · United States
  14. Jan 17, 2022Phase 3 study in Multiple Sclerosis, Relapsing-RemittingCinnagen · NCT05242133 · 168 enrolled · Iran, Islamic Republic of

TargetBeta

“A recombinant form of the endogenous cytokine human interferon (IFN) beta-1a, with antiproliferative, antiviral and immunomodulating activities”NCIt, by rule
“Interferon alpha/beta receptor agonist”ChEMBL 37, by rule

Studies

All 53 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT05242133Multiple Sclerosis, Relapsing-Remitting · Iran, Islamic Republic of3CompletedCinnagenApr 27, 2022168
NCT04860518COVID-19 · United States2TerminatedFaron PharmaceuticalsApr 4, 20227
NCT03614715Bioequivalence · Finland1CompletedCinnagenFeb 12, 201940
NCT03119701Multiple Organ Failure · Estonia, Finland, Lithuania2TerminatedFaron PharmaceuticalsSep 23, 201940
NCT03177083Multiple Sclerosis, Relapsing-Remitting · Portugal4CompletedBiogenOct 26, 202080
NCT02622724Respiratory Distress Syndrome · Belgium, Czechia, Finland and more3TerminatedFaron PharmaceuticalsMay 17, 2018301
NCT02727907Multiple Sclerosis · Russian Federation3CompletedBiocadNov 21, 2016163
NCT02269930Multiple Sclerosis · United States1CompletedBiogenDec 201430
NCT02254304Relapsing Multiple Sclerosis · Germany4CompletedMerck KGaA, Darmstadt, GermanyAug 20, 2016106
NCT02117050Multiple Sclerosis · United States4TerminatedMerck KGaA, Darmstadt, GermanyApr 20151
NCT02064816Multiple Sclerosis, Relapsing-Remitting · Germany4CompletedMerck KGaA, Darmstadt, GermanyApr 30, 2016200
NCT01863069Multiple Sclerosis · United Kingdom1CompletedTrio MedicinesOct 200177
NCT01791244Multiple Sclerosis · Germany, Sweden4CompletedMerck KGaA, Darmstadt, GermanyFeb 29, 201693
NCT01766024Healthy · Russian Federation1CompletedBiocadJun 201332
NCT01500408Multiple Sclerosis · United States1CompletedBiogenApr 2012110
NCT01416207Healthy · China1CompletedBiogenOct 201124
NCT01285401Multiple Sclerosis, Relapsing-Remitting · Austria, Denmark, Estonia and more2CompletedMerck KGaA, Darmstadt, GermanyApr 2015260
NCT01201343Multiple Sclerosis, Relapsing-Remitting4CompletedMerck KGaA, Darmstadt, GermanyJul 201079
NCT01181115Multiple Sclerosis · China3CompletedBiogenOct 201160
NCT01142466Multiple Sclerosis, Relapsing-Remitting4CompletedMerck KGaA, Darmstadt, GermanyDec 200930
NCT01119677Healthy Volunteers · United States1CompletedBiogenOct 23, 2010120
NCT01085318Multiple Sclerosis · United States4CompletedMerck KGaA, Darmstadt, GermanyFeb 29, 201238
NCT01075763Alzheimer Disease · Italy2CompletedMerck KGaA, Darmstadt, GermanyMay 200842
NCT01071083Multiple Sclerosis, Relapsing-Remitting · United States, Germany, Spain2CompletedBiogenNov 2011175
NCT01074593Healthy · Brazil1CompletedAzidus BrasilMar 201120
NCT00915577Multiple Sclerosis3CompletedBiogenApr 200674
NCT00915460Multiple Sclerosis4CompletedBiogenJun 2003408
NCT00913666Multiple Sclerosis4CompletedBiogen121
NCT00913250Multiple Sclerosis1CompletedBiogen96
NCT00912860Multiple Sclerosis2CompletedBiogenDec 2004155
NCT00828204Multiple Sclerosis · United States3CompletedBiogenJul 201095
NCT00813709Multiple Sclerosis · Argentina, Austria, Belgium and more3CompletedMerck KGaA, Darmstadt, GermanyAug 2011402
NCT00784836Multiple Sclerosis · United States3TerminatedBiogenFeb 20093
NCT00771043Multiple Sclerosis, Relapsing-Remitting4WithdrawnBiogenAug 1, 20090
NCT00725985Multiple Sclerosis · United States, Argentina, Austria and more3CompletedMerck KGaA, Darmstadt, GermanyJul 31, 2011617
NCT00616434Active Ulcerative Colitis · United States, Canada, Czech Republic and more2CompletedBiogenMar 2010123
NCT00574041Multiple Sclerosis, Relapsing-Remitting · Australia4TerminatedBiogenFeb 200819
NCT00534261Multiple Sclerosis, Relapsing-Remitting · Belgium, Luxembourg, United Kingdom4CompletedBiogen284
NCT00493116Multiple Sclerosis, Relapsing-Remitting · Australia, New Zealand4CompletedBiogenDec 200920
NCT00493077Multiple Sclerosis · Sweden4CompletedBiogenMay 20063
NCT00492466Multiple Sclerosis, Relapsing-Remitting · Finland4CompletedBiogenAug 200614
NCT00441103Multiple Sclerosis, Relapsing-Remitting3CompletedMerck KGaA, Darmstadt, GermanyNov 2008180
NCT00404352Multiple Sclerosis · Argentina, Australia, Austria and more3CompletedMerck KGaA, Darmstadt, GermanyAug 2010517
NCT00367484Multiple Sclerosis, Relapsing-Remitting4CompletedMerck KGaA, Darmstadt, GermanyJan 2006460
NCT00304252Crohn Disease · Germany, Italy, Sweden and more2TerminatedMerck KGaA, Darmstadt, Germany192
NCT00303381Colitis, Ulcerative · Germany, Israel, Netherlands and more2CompletedMerck KGaA, Darmstadt, GermanyJan 2003194
NCT00292266Multiple Sclerosis, Relapsing-Remitting3CompletedMerck KGaA, Darmstadt, GermanyJun 2002677
NCT00287079Clinically Isolated Syndrome · Canada3CompletedMerck KGaA, Darmstadt, GermanyNov 200835
NCT00249860Hepatitis C3CompletedMerck KGaA, Darmstadt, GermanyAug 2005257
NCT00168766Multiple Sclerosis, Relapsing-Remitting · Belgium, Denmark, Finland and more4CompletedBiogenNov 2008345
NCT00101959Multiple Sclerosis, Relapsing-Remitting4WithdrawnMerck KGaA, Darmstadt, Germany0
NCT00099489Polyradiculoneuropathy, Chronic Inflammatory Demyelinating · United States, Australia, Canada and more2CompletedBiogenFeb 200667
NCT00078338Multiple Sclerosis, Relapsing-Remitting · United States, Argentina, Austria and more4CompletedMerck KGaA, Darmstadt, GermanyNov 28, 2006764

How it is read

Names in the registry

  • “Interferon beta-1a”, 11 entries
  • “Rebif®”, 7 entries
  • “RNF”, 5 entries
  • “Rebif”, 4 entries
  • “SNG001”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.